FDA to GSK: No go on Avodart for prostate cancer
The Food and Drug Administration has denied GlaxoSmithKline's application to add prostate cancer reduction to the indications for Avodart, a drug used to treat an enlarged prostate.
The Food and Drug Administration has denied GlaxoSmithKline's application to add prostate cancer reduction to the indications for Avodart, a drug used to treat an enlarged prostate.